Annual Report

Overview

The report describes Polaris Group's successful unblinding of its mesothelioma clinical trial in September 2022 and its listing on the Taiwan Stock Exchange. The company reports 2022 operating income of NT$6,439,000, entirely derived from biopharmaceutical CDMO services, while its self-developed ADI-PEG 20 products remained in clinical development. The report also records 151 workers at year-end 2022 and outlines sustainable-development policies, but states that no CSR report had yet been prepared.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Publication date: 19 May 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services